Results 181 to 190 of about 12,220,634 (288)

No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease and related dementia: results from the Drug Repurposing for Effective Alzheimer's Medicines study. [PDF]

Brain Commun, 2022
Desai RJ, Mahesri M, Lee SB, Varma VR, Loeffler T, Schilcher I, Gerhard T, Segal JB, Ritchey ME, Horton DB, Kim SC, Schneeweiss S, Thambisetty M.   +12 more
europepmc   +1 more source

Temporal Trends in Intracavernosal Injection Therapy and Penile Prosthesis Implantation in the Era of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction in Australia

ANZ Journal of Surgery, EarlyView.
ABSTRACT Introduction Phosphodiesterase‐5 inhibitors (PDE5‐Is) transformed erectile dysfunction (ED) management as first‐line therapy; nonetheless, many patients require second‐ and third‐line options due to inadequate response, side effects, or contraindications.
Nicholas Gillman, Eric Chung
wiley   +1 more source

Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders. [PDF]

Aging Dis
Kumar A, Kim F, Song DK, Choung JJ.
europepmc   +1 more source

Increased bleeding risk with phosphodiesterase-5 inhibitors after left ventricular assist device implantation. [PDF]

ESC Heart Fail, 2021
Jakstaite AM, Luedike P, Schmack B, Pizanis N, Riebisch M, Weymann A, Kamler M, Ruhparwar A, Rassaf T, Papathanasiou M.   +9 more
europepmc   +1 more source

Sexual function after prostate cancer surgery or radiotherapy in an international registry

BJU International, EarlyView.
Objectives Our objective was to evaluate patient‐reported sexual function (SF) outcomes and sexual aid use 12 months after curative treatment for prostate cancer (PC). Patients & Methods This prospective registry‐based cohort study analysed men with localized or locally advanced PC enrolled in the TrueNTH Global Registry.
Y. Hess‐Busch, C. Darr, L. Püllen, M. Al‐Nader, M. Wahl, A. V. Bailey, H. Wilhalme, J. Lee, B. Hadaschik, J. Hess, on behalf of the TrueNTH Global Registry   +10 more
wiley   +1 more source

A Brief Overview of Cholinergic and Phosphodiesterase-5 Inhibitors in Diabetic Bladder Dysfunction. [PDF]

Int J Mol Sci
Kallinikas G, Haronis G, Kallinika E, Kozyrakis D, Rodinos E, Filios A, Filios P, Mityliniou D, Safioleas K, Zarkadas A, Bozios D, Karmogiannis A, Konstantinopoulos V, Konomi AM, Ektesabi AM, Tsoporis JN.   +15 more
europepmc   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Phosphodiesterase type 5 inhibitors after left ventricular assist device: no free lunch?

ESC Heart Failure, 2021
E. Wilson Grandin, Jeffrey J. Teuteberg
doaj   +1 more source

Molecular Dynamics-Assisted Discovery of Novel Phosphodiesterase-5 Inhibitors Targeting a Unique Allosteric Pocket. [PDF]

Molecules
Luo W, Liu R, Cai X, Zhou Q, Zhang C.
europepmc   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

British Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier, David Spähn, David Arturo Juarez Lopez, Judith L. Nono, Judith Seigner, Lisa Jacob, Siegfried Ussar, Robert Lukowski, Andreas L. Birkenfeld, Gencer Sancar   +9 more
wiley   +1 more source